Review of liraglutide versus sitagliptin for patients with uncontrolled type 2 diabetes: More effective HbA1c reduction with subcutaneous GLP-1 receptor agonist versus an oral DPP-4 inhibitor

Postgraduate Medicine

Volumn 122, Issue 5, 2010, Pages 185-188

  Nadeau, Daniel A ^a  

^a Nutrition Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WEIGHT REDUCTION;

EID: 79953684016     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.09.2215     Document Type: Article

References (29)

1. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2009;52(1):65-73.
2. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
3. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26(10):2929-2940.
4. Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009;122(6 suppl):S3-S10.
5. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med. 2009;122(6 suppl):S37-S50.
6. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.
7. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76-79.
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet. 1998;352(9131):837-853.
9. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
10. Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
11. Gerstein HC, Miller ME, Byington RP; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
12. Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
13. Buse JB, Ginsberg HN, Bakris GL, et al; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162-172.
14. Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D'Agostino RB Sr. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s. The Framingham Heart Study. Circulation. 2006;113(25):2914-2918.
15. Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D'Agostino RB Sr. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham Heart Study. Diabetes Care. 2008;31(8):1582-1584.
16. Pi-Sunyer X, Blackburn G, Brancati FL, et al; Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374-1383.
17. Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes. 1999;48(4):839-847.
18. Weyer C, Hanson K, Bogardus C, Pratley RE. Long-term changes in insulin action and insulin secretion associated with gain, loss, regain and maintenance of body weight. Diabetologia. 2000;43(1):36-46.
19. Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation. 2002;105(7):804-809.
20. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753-761.
21. Martin CL. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes. Diabetes Educ. 2008;34(suppl 3):66S-72S.
22. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, Macconell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24(10):2943-2952.
23. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009;94(6):1843-1852.
24. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8(4):436-447.
25. 1c target, 7%-no hypoglycaemia-no weight gain, with liraglutide vs other T2D therapies (abstract 593-P). Poster presented at the American Diabetes Association 70th Scientific Sessions: Orlando, FL; June 25-29, 2010.
26. Courreges J-P, Thiriet CM, Abbed NS. Comparative, transversal analysis of adding metformin or glimepiride therapy to liraglutide in the treatment of type 2 diabetes (abstract 737-P). Poster presented at the American Diabetes Association 70th Scientific Sessions: Orlando, FL; June 25-29, 2010.
27. 1c (abstract 764-P). Poster presented at the American Diabetes Association 70th Scientific Sessions: Orlando, FL; June 25-29, 2010.
28. Russell-Jones D, Sesti G, Garber A, Zinman B, Jensen K, Falahati A, Colagiuri S. Liraglutide causes reductions in body weight both in patients with and without gastrointestinal side effects (abstract 1886-P). Poster presented at the American Diabetes Association 70th Scientific Sessions: Orlando, FL; June 25-29, 2010.
29. Matthews D, Vilsboll T, Courreges J-P, Zychma M, Falahati A, Seino Y, Bode B. Liraglutide improves beta-cell function as assessed by HOMA-B and proinsulin: insulin ratio: meta-analysis of 6 clinical trials (abstract 1513-P). Poster presented at the American Diabetes Association 70th Scientific Sessions: Orlando, FL; June 25-29, 2010